The Phase 2 trial of IO102-IO103 in combination with KEYTRUDA for advanced head and neck cancer met its primary endpoint with a 44.4% overall response rate. It also showed a 6.6-month median progression-free survival and a 66.7% disease control rate in PD-L1 high patients with SCCHN.